Palmieri, Salvatore Rocco, S Vitagliano, O Catalano, L Cerchione, C Vincelli, I D Scopelliti, A Gentile, M Farina, G Barone, M
...
Published in
Annals of hematology
From April 2016, carfilzomib, in combination with lenalidomide and dexamethasone (KRD), became available for use in the daily practice in Italy for patients with relapsed or refractory multiple myeloma (RRMM). We performed a retrospective survey at 14 different institutions from Southern Italy in order to evaluate patient characteristics and treatm...
Porte, B Carton, M Lerebours, F Brain, E Loirat, D Haroun, L Bellesoeur, A Bach Hamba, S Kirova, Y Cottu, P
...
Published in
Breast (Edinburgh, Scotland)
Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. Emerging real-life data suggest that the efficacy of a palbociclib-based therapy is highly conserved. We report the Institut Curie hospital experience. We retrospectively reviewed ...
Rumpold, Holger Niedersüß-Beke, Dora Heiler, Cordula Falch, David Wundsam, Helwig Valenting Metz-Gercek, Sigrid Piringer, Gudrun Thaler, Josef
Published in
BMC Cancer
BackgroundMetastatic colorectal cancer (mCRC) remains a lethal disease. Survival, however, is increasing due to a growing number of treatment options. Yet due to the number of prognostic factors and their interactions, prediction of mortality is difficult. The aim of this study is to provide a clinical model supporting prognostication of mCRC morta...
Rocchi, Serena Tacchetti, Paola Pantani, Lucia Mancuso, Katia Rizzello, Ilaria di Giovanni Bezzi, Chiara Scalese, Marco Dozza, Luca Marzocchi, Giulia Martello, Marina
...
Published in
Hematological oncology
Carfilzomib-lenalidomide-dexamethasone (KRd) has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM). We conducted a retrospective analysis of 197 RRMM patients (pts) between January 2016 and March 2018 in 6 italian hematologic centers, with the aim to evaluate efficacy and safety of KRd in real-life. At KRd initiation 27...
Pepe, Sara Scalzulli, Emilia Colafigli, Gioia Di Prima, Alessio Diverio, Daniela Mancini, Marco Latagliata, Roberto Martelli, Maurizio Foà, Robin Breccia, Massimo
...
Published in
Annals of hematology
Predictive factors of response to hypomethylating agents (HMA) in elderly acute myeloid leukemia (AML) patients remain unclear in the real-life setting and no direct comparison between azacitidine (AZA) and decitabine (DEC) has been carried out. We retrospectively evaluated 110 AML patients treated with HMA (78 AZA, 32 DEC) as first-line therapy ou...
Giovannini, Mattia Mori, Francesca Barni, Simona Liccioli, Giulia Sarti, Lucrezia Novembre, Elio
Published in
Pharmacology
Adverse reactions to natural rubber latex (NRL) represent a group of clinical manifestations that include non-allergic reactions and immediate-type or delayed-type allergic reactions. NRL sublingual immunotherapy (SLIT) has been demonstrated to be an effective and safe practice for latex clinical manifestations with good patient tolerance. A pediat...
Padilla-Galo, A. Levy-Abitbol, RCh Olveira, C. Valencia Azcona, B. Pérez Morales, M. Rivas-Ruiz, F. Tortajada-Goitia, B. Moya-Carmona, I. Levy-Naon, A.
Published in
BMC Pulmonary Medicine
BackgroundBenralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficac...
Zaja, F Carpenedo, M Baratè, C Borchiellini, A Chiurazzi, F Finazzi, G Lucchesi, A Palandri, F Ricco, A Santoro, C
...
Published in
Blood reviews
Thrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is growing evidence that TPO-RAs can also trigger sustained response in 10-30% of cases after treatment tapering and discontinuation. Therefore, at least for selected responding patients, it mi...
Sposato, Bruno Camiciottoli, Gianna Bacci, Elena Scalese, Marco Carpagnano, Giovanna Elisiana Pelaia, Corrado Santus, Pierachille Maniscalco, Mauro Masieri, Simonetta Corsico, Angelo
...
Published in
Pulmonary pharmacology & therapeutics
Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. We retrospectively analyzed 1...
Fernandez Montes, A Vazquez Rivera, F Martinez Lago, N Covela Rúa, M Cousillas Castiñeiras, A Gonzalez Villarroel, P de la Cámara Gómez, J Méndez Méndez, J C Salgado Fernández, M Candamio Folgar, S
...
Published in
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. This is a retrospective study of a cohort of patients with mCRC in treatment ...
